Mike Hencke | Head, Investor Relations |
Michel Vounatsos | Chief Executive Officer |
Priya Singhal | Interim Head, Research & Development |
Michael McDonnell | Chief Financial Officer |
Umer Raffat | Evercore |
Brian Abrahams | RBC Capital Markets |
Salveen Richter | Goldman Sachs |
Tim Anderson | Wolfe Research |
Chris Raymond | Piper Sandler |
Matthew Harrison | Morgan Stanley |
Brian Skorney | Baird |
Michael Yee | Jefferies |
Robyn Karnauskas | Truist Securities |
Jay Olson | Oppenheimer |
Phil Nadeau | Cowen and Company |
Marc Goodman | SVB Securities |
Chris Schott | JPMorgan |
Paul Matteis | Stifel |
Geoff Meacham | Bank of America |
Good morning. My name is Jennifer, and I will be your conference operator today. At this time, I'd like to welcome everyone to the Biogen Third Quarter 2022 Earnings Call and Business Update. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session.